Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

NCT04657822 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: Crizanlizumab

Sponsor

Novartis Pharmaceuticals